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Abstract
Hypofunction of N-methyl-D-aspartate (NMDA) receptor-mediated signal transduction has been implicated in the
pathophysiology of schizophrenia. Post-synaptic density protein 95 (PSD95) plays a critical role in regulating the trafficking
and activity of the NMDA receptor and altered expression of the PSD95 has been detected in the post-mortem brain of
patients with schizophrenia. The study aimed to examine whether the DLG4 gene that encodes the PSD95 may confer
genetic susceptibility to schizophrenia. We re-sequenced the core promoter, all the exons, and 39 untranslated regions (UTR)
of the DLG4 gene in 588 Taiwanese schizophrenic patients and conducted an association study with 539 non-psychotic
subjects. We did not detect any rare mutations at the protein-coding sequences of the DLG4 gene associated with
schizophrenia. Nevertheless, we identified four polymorphic markers at the core promoter and 59 UTR and one single
nucleotide polymorphism (SNP) at the 39UTR of the DLG4 gene in this sample. Genetic analysis showed an association of a
haplotype (C–D) derived from 2 polymorphic markers at the core promoter (odds ratio=1.26, 95% confidence
interval=1.06–1.51, p=0.01), and a borderline association of the T allele of the rs13331 at 39UTR with schizophrenia (odds
ratio=1.19, 95% confidence interval=0.99–1.43, p=0.06). Further reporter gene assay showed that the C-D-C-C and the T
allele of the rs13331 had significant lower activity than their counter parts. Our data indicate that the expression of the DLG4
gene is subject to regulation by the polymorphic markers at the core promoter region, 59 and 39UTR of the gene, and is
associated with the susceptibility of schizophrenia.
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Introduction
Compelling evidence suggests that compromised NMDA
receptor-mediated signal transduction is implicated in the
pathophysiology of schizophrenia [1]. The NMDA receptor
hypofunction hypothesis of schizophrenia arises first from the
observation that antagonists of the NMDA receptor, such as
phencyclidine (PCP) and ketamine induced schizophrenia-like
psychosis in normal individuals and exacerbated psychotic
symptoms in chronic stable patients with schizophrenia [2].
Further evidence comes from studies reporting that combined use
of the co-activators of NMDA receptor, such as D-serine, D-
alanine, D-cycloserine, or the glycine transporter 1 inhibitor, such
as D-sarcosine, with antipsychotic drugs improves the negative
symptoms and cognitive deficits in schizophrenia [3–5]. A double-
blind study showed that D-sarcosine alone was effective in
reducing both positive and negative symptoms in acute schizo-
phrenia patients, especially in drug-naı ¨ve patients, which also
supports the involvement of reduced NMDA receptor activity in
the pathophysiology of schizophrenia [6].
Several postmortem studies of schizophrenia have reported
altered expression of NMDA receptor subunits and their
interacting molecules in various brain regions of patients with
schizophrenia [7–16], indicating that dys-regulated expression of
the NMDA receptor and its associated molecules may underlie the
pathophysiology of schizophrenia [17].
The post-synaptic density protein 95 (PSD95) is a member of
the synapse-associated protein family of scaffolding molecules that
control the organization, composition, and function of synapses
[18]. The PSD95 plays a critical role in regulating NMDA
receptor activity and its signal transduction [19]. It binds to the C-
terminal of the NMDA receptor subunits NR2A and 2B [20,21],
and controls the trafficking, clustering, and anchoring of NMDA
receptors at the postsynaptic membrane [22]. The PSD95 is
encoded by the DLG4 gene. The Dlg4 knockout mice showed
defective synaptic plasticity and impaired spatial learning [23].
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PSD95 in various brain regions of patients with schizophrenia
[7,8,10,14,16,17,24]. Taken together, these findings indicate that
the aberrant expression and function of the PSD95 may contribute
to the compromised NMDA receptor-mediated signaling in
schizophrenia. Furthermore, the DLG4 gene that encodes the
PSD95 was mapped to chromosome 17p13.1, a region linked to
schizophrenia [25]. Thus, the DLG4 gene is a reasonable
candidate gene of schizophrenia in view of the high genetic basis
of the etiology of schizophrenia. However, to our knowledge, no
mutations of the DLG4 gene associated with schizophrenia have
been identified so far.
The study aimed to investigate whether there are genetic
variants of the DLG4 that may confer an increased risk to
schizophrenia. To test this hypothesis, we re-sequenced the core
promoter, all the exons, and the 39 untranslated regions (UTR) of
the DLG4 gene in a sample of Han Taiwanese schizophrenic
patients and conducted a case-control association analysis. We also
performed reporter gene activity assay to characterize the genetic
variants at the 59 and 39ends of the DLG4 gene identified in this
study.
Results
Detection of Genetic Variants
After sequencing all the protein-coding regions of the DLG4
gene in our patients, we did not identify any mutations associated
with schizophrenia in this sample. Nevertheless, we identified six
common variants that have been reported in the single nucleotide
polymorphisms (SNP) database (http://www.dbSNP), including
rs2230178, rs6145976, rs2017365, rs739669, rs17203281, and
rs13331 from 59 to 39 of the DLG4 gene. The rs2230178 and
rs6145976 were located at putative core promoter regions, while
rs2017365 and rs739669 were located at the untranslated exon 1
of the DLG4 gene. The rs17203281 was located at exon 12, and
the rs13331 was located at the 39 UTR of exon 22 of the DLG4
gene. Locations of these variants are illustrated in Figure 1.
In Silico Analysis
In sillico analysis showed that all the four markers from the
59end of the DLG4 gene, i.e. rs2230178, rs6145976, rs2017365
and rs739669 makers, were located at transcription factors binding
sites, suggesting these variants may have regulatory influences on
the expression of the DLG4 gene. The rs17203281 was a
synonymous mutation that did not change amino acid isoleucine
at codon 432. The rs13331 at the 39UTR was located at a specific
translation control element site (differentiation control element,
DICE), indicating that it might control the translation of DLG4.
The putative regulatory element binding sites of these polymor-
phic markers are listed in Table S1.
Genetic Association Analysis
We chose the four polymorphic markers at the 59 end of the
gene (rs2230178, rs6145976, rs2017365, and rs739669) and the
marker at the 39UTR (rs13331) for further genetic association
study in view of their potential regulatory function on the
expression of DLG4 gene. The genotype distributions of these
markers did not deviate from Hardy-Weinberg equilibrium in
both the patient and control groups. Pair-wise linkage disequilib-
rium analysis showed significant linkage disequilibrium (LD)
among these five markers in both patient and control groups.
Notably, we found different LD structure between the patient and
control groups as shown in Figure 2, suggesting there might be
differences in haplotype distributions between patients and control
subjects.
Single marker association analysis showed a borderline allelic
association of the rs6145976 (p=0.08), rs739669 (p=0.04), and
rs13331 (p=0.06) with schizophrenia, as summarized in Table S2.
In haplotype-based association analysis, we found a significant
association of the haplotype C–D derived from the two
polymorphic markers located at the core promoter (rs2230178
and rs6145976, p=0.01) with schizophrenia, whereas a nominal
association of the haplotype C-D-C derived from 3 markers
(rs2230178, rs6145976, and rs2017365,p=0.03), and the haplo-
type C-D-C-C derived from the four polymorphic markers at the
59 end of the DLG4 gene (rs2230178, rs6145976, rs2017365, and
rs739669, p=0.04) with schizophrenia. The haplotype data are
listed in Table S3.
Reporter Gene Activity Assay
We further performed a reporter gene activity assay to assess the
potential regulatory function of these polymorphic variants on the
Figure 1. Schematic genomic structure of the DLG4 gene and locations of six genetic variants identified in this study. The gray box
indicates the putative core promoter region; the black box indicates the protein-coding region; the white box indicates the untranslated region.
doi:10.1371/journal.pone.0015107.g001
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constructs containing the rs2230178, rs6145976, rs2017365, and
rs739669. As shown in Figure 2A, the haplotype C-D-C-C had
significantly lower promoter activity compared to the common
haplotype C-I-T-T (p,0.001). We also assessed the reporter gene
activity of the rs13331 at the 39UTR of the DLG4 gene. As shown
in Figure 3B, the T allele of the rs1331 had significantly lower
activity than the C allele (p=0.02).
Power Analysis
The study had the power of 18.4%, 53.0%, and 83.8% to detect
the allelic relative risk of 1.1, 1.2, and 1.3, respectively, under the
following statistic parameters: multiplicative inheritance mode,
disease prevalence=0.01, risk allele frequency=0.3, and alpha
level of 0.05.
Discussion
Schizophrenia is a complex genetic disease with polygenic
involvement in its etiology. Currently, two hypotheses have been
proposed to account for the genetic basis of schizophrenia. One is
the common variant hypothesis that attributes schizophrenia to
the joint effect of multiple common genetic variants, with each
contributing a small-to-modest risk of schizophrenia [26]. The
other is the rare mutation hypothesis, which proposes that
schizophrenia is caused by rare mutations with a high clinical
penetrance, and the pathogenic mutation is highly individualized
in each affected patient or family [27]. In this study, after re-
sequenced the putative core promoter region, all the exons, and
the 39UTR regions of the DLG4 gene in our patients, we did not
find missense or frameshifting mutations in the DLG4 gene
associated schizophrenia, indicating that exonic mutations in the
DLG4 might be very rare in schizophrenia, and unlikely play a
major role in the pathogenesis of schizophrenia.
Nevertheless, we confirmed six polymorphic markers of the
DLG4 gene that have been reported in the SNP database in our
subjects, including rs2230178, rs6145976, rs2017365, rs739669,
rs17203281, and rs13331. In silico analysis showed that different
alleles of rs2230178, rs6145976, rs2017365, and rs739669 at the
59 end of the gene may have differential influences on expression
of the DLG4 gene. The results of the reporter gene assay support
the prediction from in silico analysis; the haplotypes C-D-C-C and
T-D-C-T had significant lower activity than the C-I-T-T. The
rs17203281 at exon 12 is a synonymous mutation that does not
alter the amino acid isoleucine at codon 432. Although several
studies have indicated that synonymous mutations may not be
always silent [28,29], we did not pursue the functional significance
of this marker in this study, because this marker has been reported
Figure 2. Plots of pair-wise linkage disequilibrium of the five molecular variants of the DLG4 gene in the patient group and control
subjects. (A) and (C) are results using the Haploview computer program, while (B) and (D) are results using the GOLD computer program.
doi:10.1371/journal.pone.0015107.g002
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population in a previous study [30]. The rs13331 at the 39UTR of
DLG4 was also predicted to be functional, because it was located at
the DICE site. The reporter gene assay showed C allele had a
significantly higher Renilla activity than the T allele, suggesting
the rs13331 may also play a role in regulating the expression of
DLG4.
In the genetic analysis, we found a different LD structure
derived from 4 markers at the 59 end of the gene between the
patient and control groups, suggesting that there might be different
haplotype distributions between patient and control groups. The
different LD might arise from the borderline association of the
rs6145976 (p=0.08) and the rs739669 (p=0.04) with schizophre-
nia. Further haplotype-based association analysis showed a
significant association of the haplotype C-D derived from two
markers at the core promoter region with schizophrenia
(rs2230178 and rs6145976, p=0.01), and reporter gene activity
assays showed that the haplotype C-D-C-C derived from
rs2230178-rs6145976- rs2017365-rs739669 had significant lower
promoter activity than that of the C-I-T-T, suggesting that C-D
haplotype that is associated with schizophrenia may have reduced
expression of the DLG4 gene in patients with schizophrenia.
To our knowledge, there are only two genetic association studies
of DLG4 with schizophrenia in the literature. Kawashima and
colleagues chose six SNPs (rs314253, rs13331, rs2242449,
rs390200, rs507506, rs739669) across the entire DLG4 gene and
examined their association with schizophrenia in a Japanese
sample [31]; they found no association of these SNPs and their
derived haplotypes with schizophrenia; however, we found a
borderline association of the rs13331 SNP with schizophrenia in
our sample (p=0.06). In another study, Tsai and colleagues
examined the association of two SNPs (rs2521985 at intron 2 and
rs17203281 at exon 12) of the DLG4 gene with schizophrenia in a
Han Taiwanese sample [30]; they found no association of these
two SNPs with schizophrenia in their sample.
Based on the genetic and functional analysis of the DLG4 gene
in the present study, we suggest that subjects carrying the C-D
haplotype that is associated with schizophrenia and shows a
significant low reporter gene activity may have a reduced
expression of PSD95. Similarly, subjects that carry the T allele
Figure 3. Reporter gene activity assays of molecular variants of the DLG4 investigated in this study. (A) The promoter activity of the C-D-
C-C that is associated with schizophrenia had significantly lower than that of the C-I-T-T haplotype. I: indicates two copies of the ‘‘gcgtcctgcacgccc’’of
the rs6145976; D: indicates single copy of the ‘‘gcgtcctgcacgccc’’ of the rs6145976. (B) The T allele of the rs13331 at 39UTR that is borderline
associated with schizophrenia had significantly lower activity than that of the C allele.
doi:10.1371/journal.pone.0015107.g003
DLG4 and Schizophrenia
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low reporter gene activity may also have a decreased level of
PSD95. Taken together, the present study suggests reduced DLG4
gene expression may confer increased risk to schizophrenia.
PSD95 plays an essential role in the trafficking, clustering, and
anchoring of the NMDA receptor at the postsynaptic membrane
[22]. Expression of PSD95 selectively enhances NR2A and NR2B
expression, which results in increased NR1/NR2A and NR1/
NR2B expression [21]. PSD95 also modulates the channel gating
of the NMDA receptor by increasing the channel opening rate
[32]. Hence, the reduced PSD95 expression in those subjects
carrying the C-D haplotype and the T allele of the rs13331 may
lead to a reduction of the functional NMDA receptor or a
compromised NMDA receptor-mediated signaling transduction.
Furthermore, PSD95 forms a big protein complex by
interacting directly and indirectly with many synaptic adhesion
proteins and intracellular molecules [33]. Hence, the influence of
reduced expression of the PSD95 may not be limited to the
NMDA receptor. For example, PSD95 is required for activity-
driven synapse formation [34]; PSD95 also interacts with the
dopamine D1 receptor [35] and is involved in the reciprocal
facilitating, positive feedback loop between the dopamine D1
receptor and NMDA receptor [36]; PSD95 is also involved in
neuroligin-mediated excitatory and inhibitory synapse formation
[37]; PSD95 is reported to regulate dendritic spine growth and
synaptic plasticity [38]. Taken together, reduced expression of
PSD95 may have broad and diverse influences on synaptic
plasticity and function. The clinical significance and the relevance
of these findings to the pathogenesis and pathophysiology of
schizophrenia remain to be explored.
In summary, we characterized a specific haplotype at the
promoter and a SNP at the 39UTR of the DLG4 gene that were
associated with increased liability to schizophrenia. These genetic
markers may lead to reduced expression of the PSD95 in the
brain, and exert broad and diverse influence on the pathogenesis
of schizophrenia. However, the study is limited by its small sample
size, and the borderline statistical significance. Independent studies




All subjects were Han Taiwanese. Patients fulfilling the
diagnostic criteria for schizophrenia as defined by the Diagnostic
and Statistical Manual of Mental Disorders-IV (DSM-IV) were
recruited into this study from the Department of Psychiatry, Yuli
Veterans Hospital, Hualien Armed Forced General Hospital, and
Taoyuan Armed Forced General Hospital, Taiwan. The diagnosis
of schizophrenia was based on clinical interviews and reviews of
medical records by senior psychiatrists with consensus. Exclusion
criteria included psychosis due to a general medical condition,
substance-related psychosis, and mood disorder with psychotic
features. Control subjects were recruited from subjects receiving
routine medical checkups from the Department of Family
Medicine of a general hospital at eastern Taiwan. The mental
status and history of mental illness of the control subjects were
evaluated by a senior psychiatrist; subjects diagnosed with a DSM-
IV axis I disorder were excluded. The study protocol was
approved by the Ethics Committee of Yuli Veterans Hospital,
Hualien Armed Forced General Hospital, Taoyuan Armed Forced
General Hospital, and Tzu-Chi General Hospital, Taiwan, and
written informed consent was obtained after the procedures were
fully explained. The patient group comprised 588 schizophrenia
patients (333 males, 255 females, mean age=42.46 years,
SD=11.95), while the comparison group comprised 539 subjects
(250 males, 289 females, mean age=46.00 years, SD=13.02).
Genomic DNA was prepared from peripheral blood using the
Puregene DNA purification system (Gentra Systems Inc. Minnea-
polis, MI), according to the manufacturer’s instructions.
Mutation Detection and Genotyping
The DLG4 gene (GenBank accession No. NC_000017) contains
22 exons that span approximately 30 kb at chromosome 17p13.1;
the exon 1 contains the untranslated region and the translation
start site [39]. The putative promoter of the DLG4 gene was
predicted to be located between nucleotide positions –1166 and –
1415 upstream from the ATG starting nucleotide using the
PROSCAN (http://bimas.dcrt.nih.gov/mdbio). The schematic
genomic structure of the DLG4 gene is illustrated in Figure 1. We
systematically screened mutations at the promoter region, all the
exons and their flanking intronic sequences of the DLG4 gene
in all patients using PCR-direct autosequencing. Optimal
PCR primer sequences were designed to amplify the above
regions using Primer3 (http://WWW-genome.wi.mit.edu/
cgi-bin/primer/primer3_www.cgi). Primer sequences, optimal
annealing temperatures and the size of each amplicon are listed
in Table S4. In standard PCR, genomic DNA (100 ng) was
amplified in a reaction volume of 20 ml containing 1 mM each of
sense and antisense primer, 0.2 mM of dNTP, 50 mM of KCl,
1.5 mM of MgCl2, 0.1% vol/vol of Triton X-100, 10 mM of Tris-
HCl (pH 9.0), and 2.5 U Taq polymerase. PCR cycling conditions
consisted of an initial denaturation at 95uC for 5 min, followed by
30 cycles of 95uC for 1 min, optimal annealing temperature of
each amplicon for 1 min, and 72uC for 1 min. PCR was
performed with a PTC-200 DNA engine (MJ Research, Water-
town, MA). For sequencing, aliquots of PCR products were
processed using a PCR Pre-Sequencing Kit (USB Cleveland) to
remove residual primers and dNTPs following the manufacturer’s
protocol. The purified PCR products were subjected to direct
sequencing using a ABI Prism
TM BigDye
TM Terminator Cycle
Sequencing Ready Reaction Kit Version 3.1, and a ABI
autosequencer 3730 (Perkin Elmer Applied Biosystems, Foster
City, USA), according to manufacturer’s protocol. For the case-
control association study, the genotype of each genetic variant of
the DLG4 gene in the control subjects was also determined by
PCR-based direct sequencing.
In Silico Analysis
The alteration of putative transcription factor binding sites by
the promoter variants of the DLG4 gene were evaluated using
TESS (http://www.cbil.upenn.edu/cgi-bin/tess/tess). Putative
miRNA targets at the 39UTR of the DLG4 gene were analyzed
using the program from MicroRNA.org (http://www.microrna.
org/microrna/home.do). The potential regulatory elements of the
39UTR of the DLG4 gene were assessed using UTRscan (http://
www.ba.itb.cnr.it/BIG/UTRScan/).
Genetic Association Analysis
Deviation from the Hardy-Weinberg equilibrium of the
genotype distribution in both the patient and control groups was
examined by Chi-square test. Pair-wise linkage disequilibrium
analysis of SNPs was performed using Haploview version 4.1 [40]
and GOLD-Graphic Overview of Linkage Disequilibrium [41].
Differences in allele, genotype, and estimated haplotype frequen-
cies between patients and controls were evaluated using an online
computer platform SHEsis (http://analysis.bio-c.cn) [42]. Post-
DLG4 and Schizophrenia
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Calculator (GPC, http://statgen.iop.kcl.ac.uk/gpc/) [43].
Reporter Gene Activity Assay
Genomic DNAs from the subjects were used for constructing
the inserts for the reporter gene assay. For functional character-
ization of haplotypes derived from rs2230178, rs6145976,
rs2017365, and rs739669, sense primer that contains the KpnI
recognition site linker (59-GGTACCTGGCACCAAGAG-39) and
antisense primer that contains the BglII recognition site linker (59-
AGATCTTGCTCCACACAC-39) were used to PCR amplify the
fragment from nucleotides positions –153 to –1441 upstream the
ATG starting nucleotide of the DLG4 gene. The PCR fragments
were first cloned into pCR-Blunt II-TOPO vector (Invitrogen,
CA, USA) then subcloned into the pGL3-control vector (Promega,
Madison, WI, USA), and the authenticity of three haplotypes,
designated C-I-T-T, T-D-C-T, and C-D-C-C respectively, were
verified by sequencing. Transfection of the plasmids containing
each of these three different constructs were performed in a
SKNSH neuroblastoma cell line cultured in Minimum Essential
Medium (MEM) containing 5% fetal bovine serum in 24-well
plates using LipofetamineTM2000 (Invitrogen, California, USA)
according to the manufacturer’s protocol. Each well contained 10
5
cells, 800 ng of reporter plasmid, 160 ng of pRL-TK (Promega,
Madison, WI, USA) as an internal control, and 2 mlo f
LipofetamineTM2000. Transfection was repeated 6 times for
each reporter plasmid. At 30 hours after transfection, cells were
lysed and the luciferase activities were measured using the Dual-
Luciferase Reporter Assay System according to the manufacturer’s
instructions (Promega, Madison, WI, USA). The firefly luciferase
activity was normalized against the Renilla luciferase activity in
each transfection.
For functional characterization of the c.2865T.C (rs13331),
sense primer that contains the XbaI recognition site linker (59-
TCTAGAACACACATTCCAGA-39) and antisense primer that
contains the BamHI recognition site linker (59-GGATCCTTG-
GAGTGAAGAAGG- 39) were used to obtain amplicon contain-
ing the rs13331 (c.2865T.C). The amplicon (578 bp) was first
cloned into pCR-Blunt II-TOPO vector (Invitrogen, CA, USA)
then subcloned into 39UTR of plasmid pRL-TK (Promega,
Madison, WI, USA). The authenticity of these clones was verified
by sequencing, and designated c.2865T and c.2865C, respectively.
Transfection was performed in SKNSH neuroblastoma cell line
cultured in Minimum Essential Medium (MEM) containing 5%
fetal bovine serum in 24-well plates. Each well contained 10
5 cells,
1 mg of reporter plasmid, 200 ng of pGL3-Control as an internal
control reporter, and 2 ml of LipofetamineTM2000. Every
treatment was repeated six times. At 30 hours after transfection,
cells were lysed and the luciferase activities were measured using
the Dual-Luciferase Reporter Assay System, according to the
manufacturer’s instruction. The Renilla luciferase activity was
normalized to the firefly luciferase activity, and reported as the
relative luciferase ratio. The differences in gene expression activity
between the two constructs were analyzed using the t-test, while
differences among the three groups were evaluated by analysis of
variance (ANOVA) followed by post-hoc comparison; the p value
was set at 0.05.
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